YOKOGAWA-ELECTRIC
25.3.2020 08:02:13 CET | Business Wire | Press release
Yokogawa Electric Corporation (TOKYO:6841) announces that its subsidiary Yokogawa Turkey Industrial Automation Solutions A.S. (Yokogawa Turkey) has won an order to provide a control system and field instruments for the Zerger gas-fired power plant in Turkmenistan. The order was received from Renaissance Heavy Industries, a major construction company in Turkey that is involved in the construction of this plant for Turkmenenergo, a state-owned power utility in Turkmenistan. This is Yokogawa’s first control systems order for a power plant in this country.
Turkmenistan is a resource rich country with the world’s fourth-largest natural gas reserves*1 . The country continues to experience steady economic growth thanks to its exports of natural gas and production of cotton and other agricultural products. To aid in the reconstruction of the neighboring country of Afghanistan, the Turkmen government concluded an agreement based on which it will supply electricity to that country for a ten-year period, beginning in 2018. The main source of this electricity will be the Zerger power plant, which generates power using locally-sourced natural gas. Located in the Chardzhev district of Lebap Province, approximately 600 km northeast of Ashgabat, the country’s capital, this is a simple cycle gas turbine power plant that will have three gas turbines with a combined capacity of approximately 400 MW. Sumitomo Corporation is the prime engineering, procurement and construction (EPC) contractor for this project, and the plant’s turbines and generators are being supplied by Mitsubishi Hitachi Power Systems (MHPS).
To monitor and control the plant’s three gas turbines and auxiliary facilities, Yokogawa will provide the CENTUMTM VP integrated production control system, DPharp EJATM series differential pressure and pressure transmitters, and YTA610 temperature transmitters*2 . Yokogawa Turkey will be in charge of providing engineering and support services for the installation and commissioning of this system, and will complete work on this project by September of this year. To provide support services, Yokogawa opened a sales and after-sales office in Turkmenistan in August 2015.
One of the Sustainable Development Goals for the year 2030 that were adopted at the UN Sustainable Development Summit is to ensure the provision of affordable and clean energy. Natural gas is an energy source whose combustion emits less CO2 than oil or coal, and as such is regarded as an important means for achieving a low carbon society. Taking advantage of its strong expertise and excellent track record in natural gas related plant construction projects, Yokogawa is helping to ensure the stable supply of power in markets all over the world, including Central Asia.
*1 Source: BP Statistical Review of World Energy 2019
*2 CENTUM VP is a system in the company’s OpreXTM
Control and Safety System family. DPharp EJA series differential pressure and pressure transmitters and YTA610 temperature transmitters are products in the OpreX Field Instruments family.
For more information
Industries -Power-
https://www.yokogawa.com/industries/power/
Distributed Control System (DCS)
https://www.yokogawa.com/solutions/products-platforms/control-system/distributed-control-systems-dcs/
Field Instruments
https://www.yokogawa.com/solutions/products-platforms/field-instruments/
About Yokogawa
Founded in 1915, Yokogawa engages in broad-ranging activities in the areas of measurement, control, and information. The industrial automation business provides vital products, services, and solutions to a diverse range of process industries including oil, chemicals, natural gas, power, iron and steel, and pulp and paper. With the life innovation business, the company aims to radically improve productivity across the pharmaceutical and food industry value chains. The test & measurement, aviation, and other businesses continue to provide essential instruments and equipment with industry-leading precision and reliability. Yokogawa co-innovates with its customers through a global network of 113 companies spanning 60 countries, generating US$3.6 billion in sales in FY2018. For more information, please visit www.yokogawa.com .
The names of corporations, organizations, products, services and logos herein are either registered trademarks or trademarks of Yokogawa Electric Corporation or their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200325005013/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom